Mark Shilkrut

Mark Shilkrut, M.D., Ph.D., joined Olema Oncology in January 2023 as Vice President, Clinical Development. Dr Shilkrut previously served as Head of Global Clinical Development at Innovent Biologics USA, where he led the clinical development of immuno-oncology molecules and antibody-drug conjugates in the U.S. and Europe. Prior to Innovent Biologics, Dr. Shilkrut held clinical development roles at Novartis and Amgen, where he led registrational studies and was instrumental in the approvals of several oncology drugs, including: Imlygic® for the treatment of advanced melanoma, Kisqali® for the treatment of metastatic hormone-receptor-positive breast cancer, and Tafinlar® and Mekinist® for the adjuvant treatment of BRAFV600 melanoma. In his last role at Novartis, he served as Global Clinical Program Head and oversaw early- and late-phase drug development for the treatment of gastrointestinal cancers.

Dr. Shilkrut conducted his residency in Israel where he is board certified in radiation and medical oncology. He completed a clinical fellowship in radiation oncology at the University of Michigan, Ann Arbor. Dr. Shilkrut , holds B.A., M.D. and Ph.D. degrees from the Medical Scientist Program at Technion - Israel Institute of Technology in Haifa, Israel. He has authored and co-authored more than 30 articles in peer-reviewed journals.